Cryo-Cell International (NYSEAMERICAN:CCEL) Share Price Crosses Below 200-Day Moving Average – What’s Next?

Shares of Cryo-Cell International Inc. (NYSEAMERICAN:CCEL) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $4.98 and traded as low as $4.39. Cryo-Cell International shares last traded at $4.55, with a volume of 3,377 shares traded.

Cryo-Cell International Stock Performance

The business’s 50 day moving average is $4.58 and its 200 day moving average is $4.98. The company has a market capitalization of $36.67 million, a price-to-earnings ratio of -151.62 and a beta of 0.66.

Insider Buying and Selling

In related news, CEO David Portnoy bought 6,449 shares of the stock in a transaction that occurred on Tuesday, September 16th. The stock was bought at an average cost of $4.46 per share, for a total transaction of $28,762.54. Following the purchase, the chief executive officer directly owned 818,369 shares of the company’s stock, valued at approximately $3,649,925.74. This trade represents a 0.79% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In the last ninety days, insiders have purchased 124,381 shares of company stock valued at $551,960. 38.59% of the stock is owned by company insiders.

About Cryo-Cell International

Cryo-Cell International, Inc engages in the cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, and kidney disease, ALS, wound healing, auto-immune diseases, multiple sclerosis, Alzheimer's disease, Parkinson's diseases.